文献速递其他结缔组织病

早期免疫抑制治疗对系统性硬化症间质性肺病发生的预防作用

Preventive effects of early immunosuppressive treatment on the development of interstitial lung disease in systemic sclerosis.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

基于EUSTAR数据库与奈梅亨系统性硬化症队列,纳入1052例确诊后首次启用免疫抑制治疗且高分辨率CT无间质性肺病征象的成人患者,比较早期(病程≤3年)与晚期启动免疫抑制对间质性肺病发生及用力肺活量变化轨迹的影响。早期治疗组间质性肺病风险比为1.13(95%CI:0.93,1.38),两组用力肺活量占预计值百分比轨迹相当,未证实早期启动免疫抑制可预防间质性肺病。

要点

  • 早期(病程≤3年)与晚期启动免疫抑制相比,间质性肺病风险比为1.13(95%CI:0.93,1.38)。
  • 两组用力肺活量占预计值百分比变化轨迹相当。
  • 平均随访3.6(标准差1.4)年间间质性肺病发生率为46.6%。

核心结论

  • 研究未证实早期启动免疫抑制治疗相较晚期启动对间质性肺病发生具有预防作用。
  • 作者指出结果需谨慎解读,考虑队列富集高炎症、抗拓扑异构酶I抗体阳性患者、适应证混杂及生物制剂使用者极少。

研究设计与样本

  • 研究基于EUSTAR数据库与奈梅亨系统性硬化症队列构建队列。
  • 纳入确诊系统性硬化症后首次启动免疫抑制治疗(吗替麦考酚酯、甲氨蝶呤、环磷酰胺、托珠单抗或利妥昔单抗)且高分辨率CT无间质性肺病征象的成人患者。
  • 比较早期(病程≤3年)与晚期启动免疫抑制者的无间质性肺病生存及用力肺活量占预计值百分比变化轨迹,随访至5年。
  • 共1052例患者符合纳入标准。

主要发现

  • 早期治疗组547例(52%),男性、弥漫性皮肤型(53.1% vs 36.5%)及抗拓扑异构酶I抗体阳性(51.1% vs 42.7%)比例更高。
  • 多数患者使用甲氨蝶呤(60.1%),仅少数使用生物制剂(1.7%)。
  • 平均(标准差)3.6(1.4)年随访期间间质性肺病发生率为46.6%。
  • 校正混杂因素后,早期治疗组间质性肺病风险比为1.13(95%CI:0.93,1.38)。
  • 两组用力肺活量占预计值百分比变化轨迹相当。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 队列富集高炎症、抗拓扑异构酶I抗体阳性患者。
  • 存在适应证混杂。
  • 接受生物制剂治疗的患者极少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypothesizing that early treatment yields improved prognosis, we aimed to investigate how the timing of immunosuppressive treatment relates to interstitial lung disease (ILD) development and the course of pulmonary function in systemic sclerosis (SSc). METHODS: A cohort was created using data from the EUSTAR database and Nijmegen Systemic Sclerosis cohort, including adult patients who started their first immunosuppressive treatment (i.e. mycophenolate mofetil, methotrexate, cyclophosphamide, tocilizumab or rituximab) after SSc diagnosis, and no signs of ILD on high-resolution CT. ILD-free survival and the course of forced vital capacity (FVC) % predicted were assessed for up to 5 years' follow-up comparing patients who started early (disease duration ≤3 years) vs late with immunosuppression. RESULTS: 1052 patients met the eligibility criteria. The early treatment group (n = 547, 52%) showed a higher prevalence of male sex, diffuse cutaneous subtype (53.1% vs 36.5%), and anti-topoisomerase-I antibody (ATA, 51.1% vs 42.7%). Most patients were treated with methotrexate (60.1%), whereas only a few patients were treated with biologics (1.7%). The incidence of ILD was 46.6% after mean (s.d.) 3.6 (1.4) years; the hazards ratio for ILD in the early treatment group was 1.13 (95% CI: 0.93, 1.38) after adjustment for confounders. FVC % predicted trajectories were comparable between groups. CONCLUSION: Our findings did not confirm a preventive role of early initiation of immunosuppressive therapy vs late initiation on ILD development. However, our findings should be interpreted with caution, considering the high inflammatory, ATA-positive enriched nature of the cohort, confounding by indication, and that very few patients were treated with biologics.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Velauthapillai A, Bootsma MFR, Bruni C, et al. Preventive effects of early immunosuppressive treatment on the development of interstitial lung disease in systemic sclerosis. Rheumatology (Oxford). 2025. PMID: 39037917. doi:10.1093/rheumatology/keae375

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。